Hepatitis B and C Therapeutics Market to hit US$ 20.83 billion by 2033: Latest Drugs, Clinical Trials & Forecasts

global hepatitis B and C therapeutics market size reached US$ 17.02 billion in 2024 is expected to reach US$ 20.83 billion by 2033, growing at a CAGR of 3.4% during the forecast period 2025-2033.

United States Hepatitis B & C Therapeutics Market size in 2024: USD 4.3 B and projected to reach USD 7.4 B by 2032 with a CAGR of 7.2% (2025-2032)

Japan Hepatitis B & C Therapeutics Market size in 2024: USD 1.0 B and projected to reach USD 1.6 B by 2032 with a CAGR of 5.3% (2025-2032)

United States: Recent Industry Developments
✅ October 2025: Gilead Sciences advanced new antiviral candidates targeting drug-resistant Hepatitis B strains.
✅ September 2025: Merck expanded access programs for Hepatitis C direct-acting antivirals across underserved populations.
✅ August 2025: FDA approved combination therapies offering shorter treatment durations for Hepatitis C.

Japan: Recent Industry Developments
✅ October 2025: Daiichi Sankyo developed next-generation therapeutics for chronic Hepatitis B patients with improved safety profiles.
✅ September 2025: Collaborative clinical trials underway focusing on personalized medicine approaches in Hepatitis C treatment.
✅ August 2025: Japanese research institutes advanced biomarker discovery to predict treatment response in Hepatitis B and C.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hepatitis-b-and-c-therapeutics-market?kb

Key Highlights From This Report

1. North America leads the hepatitis B and C therapeutics market, holding the largest revenue share of 43.5% in 2024.

2. The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of 8.1% during the forecast period.

3. By therapeutic class, the Nucleoside/Nucleotide Analogues (NAs) segment dominates the market with a revenue share of 46.1% in 2024.

Key Players:

Gilead Sciences, Inc, AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, Roche Holding AG, Dynavax Technologies Corporation, VBI Vaccines

Key Development:

1. A 12-week sofosbuvir-based treatment can cost between USD 25,000 and USD 90,000 in developed markets, whereas chronic Hepatitis B therapies range from USD 300 to USD 1,200 annually.

2. In August 2025, Precision BioSciences, Inc. announced updated results from the ELIMINATE-B trial as of July 28, 2025. The trial is evaluating PBGENE-HBV in chronic hepatitis B patients, with Cohort 1 completed at a 0.2 mg/kg dose and initial safety data available from Cohort 2 at 0.4 mg/kg. The study is assessing multiple ascending dose levels, administering three doses per level, in HBeAg-negative patients currently receiving nucleos(t)ide analog therapies.

3. In March 2024, Gilead Sciences, Inc. announced that the FDA approved the supplemental new drug application for Vemlidy (tenofovir alafenamide) 25 mg tablets, allowing its use as a once-daily treatment for chronic hepatitis B in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease.

Growth Forecast Projected:

The Global Hepatitis B & C Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Latest M&A Activity

➠ Pharmaceutical and biotech sectors targeting HBV and HCV continue to see moderate M&A focused on expanding antiviral pipelines and improving manufacturing capabilities.​

➠ Investment in companies developing next-gen immunotherapies and curative approaches for chronic HBV infections are rising, exemplified by funding deals and licensing agreements.

Research Process:

Both primary and secondary data sources have been used in the global Hepatitis B & C Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=hepatitis-b-and-c-therapeutics-market?kb

Key Segments:

By Indication: (Hepatitis B (HBV), Hepatitis C (HCV))

By Route of Administration: (Oral, Injectable)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Hepatitis B & C Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Hepatitis B & C Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hepatitis-b-and-c-therapeutics-market?kb

Recent Product Launches and Clinical Trials

✦ Phase II B-SUPREME trial is underway with oral capsid assembly modulator ALG-000184 for chronic HBV, comparing its efficacy and safety to tenofovir disoproxil fumarate in treatment-naïve patients. Results are expected in 2026-2027.​

✦ TherVacB, a novel therapeutic vaccine for chronic hepatitis B, entered Phase 1b/2a clinical trials in 2025, evaluating safety, tolerability, and immune response in patients across multiple countries.​

✦ For HCV, Atea Pharmaceuticals initiated global Phase 3 C-FORWARD and C-BEYOND trials with bemnifosbuvir+ruzasvir regimens offering shorter treatments with improved cure rates, especially for genotype 3 infections.​

✦ Biocon's CIMIVIR-L, a once-daily oral fixed-dose combination for HCV, continues to strengthen access to affordable treatment in India and emerging markets

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.